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Abstract
Background: Spinal cord stimulation (SCS) and percutaneous myocardial laser revascularisation
(PMR) are treatment modalities used to treat refractory angina pectoris, with the major aim of such
treatment being the relief of disabling symptoms. This study compared the change in myocardial
perfusion following SCS and PMR treatment.
Methods: Subjects with Canadian Cardiovascular Society class 3/4 angina and reversible perfusion
defects as assessed by single-photon emission computed tomographic myocardial perfusion
scintigraphy were randomised to SCS (34) or PMR (34). 28 subjects in each group underwent
repeat myocardial perfusion imaging 12 months post intervention. Visual scoring of perfusion
images was performed using a 20-segment model and a scale of 0 to 4.
Results: The mean (standard deviation) baseline summed rest score (SRS) and stress scores (SSS)
were 4.6 (5.7) and 13.6 (9.0) in the PMR group and 6.1 (7.4) and 16.8 (11.6) in the SCS group. At
12 months, SRS was 5.5 (6.0) and SSS 15.3 (11.3) in the PMR group and 6.9 (8.2) and 15.1 (10.9) in
the SCS group. There was no significant difference between the two treatment groups adjusted for
baseline (p = 1.0 for SRS, p = 0.29 for SSS).
Conclusion: There was no significant difference in myocardial perfusion one year post treatment
with SCS or PMR.
Introduction
The SPiRiT trial is an open label, single-centre, parallel
group randomised trial comparing percutaneous myocar-
dial laser revascularisation (PMR) with spinal cord stimu-
lation (SCS) in patients with refractory angina pectoris
[1]. These techniques have been shown to improve symp-
tom control [2-6] in this group, although there is debate
as to the mechanisms underlying the clinical response [7-
Published: 28 February 2008
Trials 2008, 9:9 doi:10.1186/1745-6215-9-9
Received: 24 October 2007
Accepted: 28 February 2008
This article is available from: http://www.trialsjournal.com/content/9/1/9
© 2008 Khan et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Trials 2008, 9:9 http://www.trialsjournal.com/content/9/1/9
Page 2 of 6
(page number not for citation purposes)
10]. In accordance with the previous studies on laser
revascularisation carried out at this institution [2,3,11]
and with the recommendations of the European Society
of Cardiology Joint Study Group [12], the presence of a
reversible perfusion defect was an inclusion criterion for
this study. Perfusion imaging was repeated 12 months
post intervention in order to determine whether SCS and
PMR treatment lead to an improvement in perfusion, a
possible mechanism of action of these therapeutic modal-
ities, and whether such change correlated with change in
angina score as measured by CCS class.
Methods
The inclusion/exclusion criteria and methods of the
SPiRiT trial have been previously reported [1]. Briefly, this
open label, single centre, parallel group randomised con-
trolled trial was carried out in a tertiary referral centre for
patients with cardiovascular disease. The main inclusion
criteria were limiting angina despite maximally tolerated
antianginal medication, angiographically documented
coronary disease unsuitable for conventional revasculari-
sation (this judgement was made by a Consultant Inter-
ventional Cardiologist in conjunction with the referring
Consultant Cardiologist/Cardiothoracic surgeon) and
reversible ischaemia on Tc-99m sestamibi scanning.
Exclusion criteria included myocardial wall thickness < 8
mm in the areas to be treated by PMR, implanted pace-
makers or defibrillators or comorbidity that was consid-
ered by the assessing clinician to be of greater significance
than angina pectoris. Ethical approval was obtained from
Huntingdon Local Research Ethics Committee (reference
H00/557) prior to study commencement and all subjects
gave informed consent in accordance with the Declaration
of Helsinki.
68 subjects were randomised, of whom 34 were treated
with SCS and 34 with PMR. Perfusion scanning was per-
formed at baseline and 12 months post intervention. A 2-
day protocol was followed. The rest scan was performed
with 400 MBq of Tc-99m sestamibi being injected into a
peripheral vein whilst the patient was in a fasted state.
Pharmacological stress was performed with adenosine at
an infusion rate of 140 mcg/kg/min for 6 minutes used as
the stress agent in more than 90% of cases. The same dose
of Tc-99m sestamibi was administered 3 minutes into the
infusion. Dobutamine was used as an alternative stress
agent in subjects with significant reversible airways dis-
ease. The same stress agent was used for the pre- and post-
treatment scans for each individual patient. All scans were
performed a minimum of one hour after injection after a
fatty meal. A single-headed Elscint Apex SP4 gamma cam-
era with a low energy collimator, a 64 × 64 matrix and a
6.9 mm pixel size (Elscint Ltd, Haifa, Israel) was used.
Acquisitions were obtained in step and shoot mode, with
64 projections over a 180-degree circular orbit, with a
three-degree increment, a matrix size of 64 × 64 and 18
seconds/projection. The studies were reconstructed using
filtered backprojection without attenuation or scatter cor-
rection and realigned along the heart axis.
Scintigraphic image analysis
For perfusion analysis the left ventricle was divided into
20 segments, with 3 radial layers of 6 segments and two
apical segments. All images were visually assessed by con-
sensus of 2 experienced observers blinded to clinical data.
Perfusion was scored semiquantitatively using a 5-point
scale (0 = normal uptake; 1 = equivocal uptake; 2 = mod-
erately reduced uptake; 3 = severely reduced uptake and 4
= no uptake) [13,14]. The summed stress score (SSS) and
the summed rest score (SRS) were defined as the sum of
all the scores on the stress and rest images respectively
with the summed difference score (SDS) being the differ-
ence between the SSS and the SRS. These scores were cal-
culated for each patient at baseline and at 1-year follow-
up. An example from a subject treated with PMR is shown
in Figure 1.
Statistical analysis
The CCS class was compared using the Mantel-Haenszel
test with class as a linear trend. Significant improvement
Example Scintigraphic Rest and Stress Images pre (upper panel) and 1-year post treatment (lower panel) with PMR to the ant rior wallFigure 1
Example Scintigraphic Rest and Stress Images pre 
(upper panel) and 1-year post treatment (lower 
panel) with PMR to the anterior wall.
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in CCS was defined as at least a 2-class decrease and the
proportion of patients who had a significant improve-
ment in each group was compared using Fisher's exact
test. The SSS, SRS and SDS were summarised as the mean
and standard deviation for each group. In order to assess
the effect of treatment on these scores generalised linear
models with normal link were used with baseline score
and group as independent variables and one-year score as
the dependent variable. The treatment effect and 95%
confidence intervals from these models are reported.
Since the distributions of the scores were not completely
symmetrical these results were re-assessed against the
results of Mann-Whitney U tests, comparing the two
groups for differences between baseline and one year.
Results
Patient characteristics
Baseline and follow-up imaging was available in 56
patients (28 in each group). The commonest reasons for
failure to complete follow-up scanning were withdrawal
from the study or patient refusal. The baseline characteris-
tics are as shown in table 1. Analysis of the baseline stud-
ies from the 12 patients who did not undergo repeat
scanning at one year did not suggest that these patients
differed significantly from the group as a whole. Antiangi-
nal medication did not change during the period of fol-
low-up.
At baseline, all patients were in CCS class 3 or 4. Nineteen
(68%) of PMR and 17 (61%) of SCS patients were in class
3 (p = 0.781). At one year more SCS patients were in CCS
class 1 or 2 (Table 2) and the difference was marginally
significant at the traditional level (p = 0.059).
Four PMR patients had a 2-class improvement in CCS
compared to nine SCS patients who had a 2 class and 2
who had a 3 -class improvement (Table 3). Again, the
greater proportion of patients with a significant improve-
ment in CCS class in the SCS group was close to signifi-
cant at traditional levels (p = 0.068).
Perfusion results
Summed scores were available for 28 PMR and 28 SCS
patients at both baseline and one year after treatment. The
data are summarised in table 4. Adjusting for baseline
there was no significant difference between treatment
groups at one year in SRS (-0.004 (95%CI: -2.1, 2.1), p =
1.00). For the SSS the SCS group was 2.4 lower than the
PMR group after adjusting for baseline but this did not
reach significance (-2.4 (95% CI: -6.8, 2.0), p = 0.29).
Similarly, for the SDS the SCS group was 2.4 lower than
the PMR group and again this did not reach statistical sig-
nificance (-2.4 (95%CI: -6.2, 1.3), p = 0.21). The Mann-
Whitney U test gave similar results for all 3 measures.
Adverse Events
Sixty-seven non-fatal adverse events were recorded in the
first year for the 56 patients with baseline and one year
imaging (Table 5). The SCS group reported significantly
more adverse events than the PMR group (p < 0.001).
Forty-nine events occurred in 17 patients in the SCS
group, with 22 events categorised as being related to the
SCS procedure. Eleven patients in the PMR group reported
18 adverse events. Three events were related to the PMR
procedure, one of which occurred in a patient randomised
to SCS. Of the 42 events not related to the procedure 36
were related to the underlying disease and the difference
between the groups was not significant (p = 0.126).
Table 1: Baseline Characteristics
PMR (n = 28) SCS (n = 28)
Mean age in years (SD) 62.3 (9.7) 64.4 (7.5)
Previous revascularisation 28 (100%) 28 (100%)
Baseline medication
Beta-blockers 22 (79%) 23 (82%)
Calcium channel blockers 22 (79%) 23 (82%)
Aspirin 24 (86%) 26 (93%)
Nicorandil 26 (93%) 24 (86%)
Long-acting nitrates 23 (82%) 21 (75%)
ACE -inhibitors 13 (46%) 14 (50%)
Follow-up medication
Beta-blockers 20 (71%) 24 (86%)
Calcium channel blockers 20 (71%) 23 (82%)
Aspirin 23 (82%) 23 (82%)
Nicorandil 25 (89%) 22 (79%)
Long-acting nitrates 23 (82%) 22 (79%)
ACE – inhibitors 13 (46%) 15 (54 %)
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Discussion
Refractory angina pectoris is an increasingly common
clinical problem with significant associated morbidity.
Many different treatment modalities have been reported
to alleviate symptoms and hence improve quality of life
for patients with this condition. When assessing the effi-
cacy of such therapies it is important to acknowledge that
because angina is a symptom, it is subjective in nature.
This is particularly so in the situation of medical devices,
where a significant placebo effect is known to exist [3,4].
Consequently, caution must be exercised in the interpre-
tation of studies based solely upon anginal symptoms, or
other subjective endpoints such as hospital admissions,
and exercise performance, although from the individual
patient's point of view, these endpoints may be the most
important.
Previous data assessing changes in perfusion following
both SCS and PMR has been inconclusive. Three PET stud-
ies of myocardial perfusion and SCS in humans have been
published. Two studies did not demonstrate any increase
in the primary outcome measure, total myocardial blood
flow following SCS. [15-17] The third study, which only
assessed resting flow, reported an increase in total myo-
cardial blood flow. Two of the studies, as part of a second-
ary analysis, reported "homogenisation of flow" i.e. when
comparing regional flow after SCS to baseline results,
blood flow increased in regions of low baseline flow and
fell in regions of high baseline flow. This flow homogeni-
sation, which was suggested to underpin the beneficial
effects of SCS could also be explained by the phenome-
non of regression to the mean. Diedrichs et al.[18]
reported an improvement in myocardial perfusion in
some patients 12 months after treatment with SCS. How-
ever, this improvement, unlike improvements in symp-
tom severity, functional capacity and quality of life, was
not demonstrated at 3 months rasing the possibility that
the perfusion changes were secondary to improved func-
tional capacity. Similarly, following PMR treatment, most
clinical studies have failed to show a consistent change in
myocardial perfusion to correspond to improvements
recorded in angina class and exercise capacity, although
investigators have reported improvements in myocardial
perfusion some using different laser systems to that used
here [8,10,19-21]. Some of these differences may be
explained by patient and laser system selection. The laser
used in this study was the Cardiogenesis system which dif-
fers from the Biosense DMR[21] system in that angio-
graphic and perfusion data are used to identify areas to be
treated by laser as opposed to electromechanical mapping
of the left ventricular cavity, and in that the DMR laser is
Table 5: Adverse Events reported in the first year
SCS PMR
Disease related
Unstable angina 16 9
Myocardial infarction 2 0
Worsening angina 6 3
Total disease related 24 12
SCS related
Infection of SCS system 0 NA
Undesirable change in stimulation 14 NA
Pain at neurostimulator site 5 NA
Neurostimulator migration 2 NA
Lead migration 1 NA
PMR related
Pseudoaneurysm 0 1
Groin haematoma 1 1
Other miscellaneous 2 4
TOTAL EVENTS 49 18
Total Events excluding SCS/PMR related 26 16
Table 3: Change in CCS Class
Change in CCS at 1 year PMR (n = 28) SCS (n = 28)
-3 0 (0%) 2 (7%)
-2 4 (14%) 9 (32%)
-1 11 (39%) 9 (32%)
0 9 (32%) 6 (21%)
1 4 (14%) 2 (7%)
Table 2: CCS Class at year one
CCS class at 1 year PMR (n = 28) SCS (n = 28)
1 1 (4%) 6 (21%)
2 12 (43%) 13 (46%)
3 7 (25%) 4 (14%)
4 8 (29%) 5 (18%)
Table 4: Mean and standard deviation for summed scores by 
treatment group
Variable PMR group (n = 28) SCS group (n = 28)
Baseline
Summed rest score 4.6 (5.7) 6.1 (7.4)
Summed stress score 13.6 (9.0) 16.8 (11.6)
Summed difference score 9.0 (8.4) 10.6 (10.2)
One year
Summed rest score 5.5 (6.0) 6.9 (8.2)
Summed stress score 15.3 (11.3) 15.1 (10.9)
Summed difference score 9.8 (8.7) 8.3 (9.1)
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a 'contact' system such that the depth of the channels cre-
ated is significantly less.
This is the first study to compare change in perfusion in
refractory angina for two active treatments. There was no
significant difference in perfusion between or within treat-
ment groups at year one. There are several limitations of
this study and these may account for this negative finding.
Although it is known that the symptoms of refractory
angina pectoris remain remarkably constant in most
patients [22], it is clear that perfusion defects can vary con-
siderably, independently of study processing variables
[23]. In addition, perfusion defects were assessed using
adenosine as a selective vasodilator with sestamibi as the
tracer agent. Patients with refractory angina often have dif-
fuse coronary artery disease with impaired fractional flow
reserve hence it may not be possible to demonstrate a
change in perfusion, even in the presence of significant
ischaemia. Also, this study was relatively small and was
not powered for this secondary outcome measure.
Conclusion
In conclusion, this study has not demonstrated a signifi-
cant change in perfusion one -year post treatment. We
would recommend that studies of refractory angina thera-
pies include objective measures of myocardial perform-
ance and that consideration be given to techniques other
than myocardial perfusion imaging using adenosine as a
stressor.
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